NCT01629615 - A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Breast Cancer

Interventions

DRUG

BKM120

BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression

Trial Locations (7)

Hospital Universitario 12 de Octubre, Madrid

Instituto Valenciano de Oncología, Valencia

Hospital Clínico Universitario de Valencia, Valencia

Dana-Farber at Faulkner Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Hospital Universitario Vall d´Hebron, Barcelona